Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478904 | 0.91 | LMNA (0.61) | LMNAMEN1KMT2AMAPTCYP2C9 | |
| SCHEMBL10540044 | 0.86 | LMNA (0.55) | LMNAMEN1KMT2AMAPTCYP2C9 | |
| Sulfameter SCHEMBL79417 | 0.79 | LMNA (1.00) | LMNAMEN1KMT2AMAPTCYP2C9 | |
| Sulfameter SCHEMBL11137116 | 0.78 | LMNA (0.97) | LMNAMEN1KMT2AMAPTCYP2C9 | |
| Sulfameter SCHEMBL27709233 | 0.78 | LMNA (0.97) | LMNAMEN1KMT2AMAPTCYP2C9 | |
| Sulfameter SCHEMBL17593237 | 0.78 | LMNA (0.97) | LMNAMEN1KMT2AMAPTCYP2C9 | |
| SCHEMBL2176380 | 0.76 | MAPT (0.68) | LMNAMEN1KMT2AMAPTCYP2C9 | |
| SCHEMBL6557184 | 0.75 | MAPT (0.63) | LMNAMEN1KMT2AMAPTCYP2C9 | |
| SCHEMBL9732799 | 0.75 | DHFR (0.58) | LMNAMEN1KMT2ADHFRTSHR | |
| Sulfameter SCHEMBL28250749 | 0.75 | LMNA (0.89) | LMNAMEN1KMT2AMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038399-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | Motif BioSciences Inc. | 2020-02-06 | — | — | US | claimed |
| EP-3538094-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | Motif Biosciences, Inc. (US) | 2019-09-18 | — | — | EP | claimed |
| WO-2018144086-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | MOTIF BIOSCIENCES, INC. (US) | 2018-08-09 | — | — | WO | claimed |
| US-20180133218-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | HERCULES TECHNOLOGY MANAGEMENT CO III LLC | 2018-05-17 | — | — | US | claimed |
| US-4315931-A | MICROBIOCIDES, INFECTIOUS DISEASES | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | claimed |
| US-20200038399-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | Motif BioSciences Inc. | 2020-02-06 | — | — | US | disclosed |
| EP-3538094-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | Motif Biosciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018144086-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | MOTIF BIOSCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180133218-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | HERCULES TECHNOLOGY MANAGEMENT CO III LLC | 2018-05-17 | — | — | US | disclosed |
| EP-1230224-B1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1278742-B1 | CHROMENYLMETHYLPYRIMIDINEDIAMINES AS ANTIBACTERIAL AGENTS | BASILEA PHARMACEUTICA AG (CH) | 2004-12-15 | — | — | EP | disclosed |
| US-6818649-B2 | 5-(8-ALKOXY)-2,2-SUBSTITUTED-2H-CHROMEN-6-YLMETHYL)-PYRIMIDINE-2,4 -DIAMINE DERIVATIVES USEFUL FOR TREATING INFECTIOUS DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2004-11-16 | — | — | US | disclosed |
| US-4189581-A | BACTERICIDES, POTENTIATORS OF SULFA DRUGS | BASF AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
| EP-0000335-A1 | Esters of N-pyrimidinyl-carboximidic acid, process for their preparation and medicines containing them. | BASF Aktiengesellschaft (DE) | 1979-01-24 | — | — | EP | disclosed |
| EP-0000336-A1 | N-benzylpyrimidinyl-amidines, process for their preparation and medicines containing them | BASF Aktiengesellschaft (DE) | 1979-01-24 | — | — | EP | disclosed |
| EP-0000334-A1 | 2,4-Diamino-5-benzyl-pyrimidines, process for their preparation and medicines containing them | BASF Aktiengesellschaft (DE) | 1979-01-24 | — | — | EP | disclosed |
| US-4076810-A | Benzylpyrimidine antibacterial composition | HOFFMANN-LA ROCHE INC. (US) | 1978-02-28 | — | — | US | disclosed |
| US-4039543-A | SUBSTITUTED BY AMINE, N-RING, AMIDE, CARBAMATE, UREA | HOFFMANN-LA ROCHE INC. (US) | 1977-08-02 | — | — | US | disclosed |
| US-4024145-A | Benzylpyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1977-05-17 | — | — | US | disclosed |
| US-3931181-A | BACTERICIDE | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133218-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | NISCH, KIT, MGAM | LMNA 852/4885MEN1 1282/4885KMT2A 524/4885 |
| US-20200038399-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | NISCH, KIT, MGAM | LMNA 852/4885MEN1 1282/4885KMT2A 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.